BHST BioHarvest Sciences Inc.
BioHarvest Sciences Inc. operates as a biotechnology company in Israel and the United States. It operates through two segments: Products and CDMO Services. The company develops botanical synthesis platform technology to …
Industry Peers
Packaged Foods| Headline | Source | Time |
|---|---|---|
Older | ||
 BioHarvest Sciences launches buyback of up to 5% of shares BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) said Tuesday its board has authorized a share repurchase program covering up to 5% of its outstanding common shares. The company, which develops and manufactures proprietary plant-based compositions for customers, partners and its own... | ||
 BioHarvest Sciences launches single-dose VINIA Daily Chews BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) has launched single-dose VINIA Daily Chews, a new delivery format for its proprietary red-grape cell composition designed to expand VINIA's addressable market. VINIA is a natural, non-GMO powder derived from red grape cells and is BioHarvest's... | ||
 BioHarvest Sciences plans Tel Aviv Stock Exchange dual listing BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) plans to pursue a dual listing of its ordinary shares on the Tel Aviv Stock Exchange (TASE), with trading expected to begin on September 8, 2026. The company, which is listed on the Nasdaq Capital Market, expects the TASE listing to provide... | ||
 BioHarvest Sciences (BHST) Q2 2026 Earnings Call Transcript Rakib outlines shift toward CDMO and secures $20M-$30M fragrance contract. | ||
BioHarvest Sciences Inc (BHST) (Q2 2026) Earnings Call Highlights: Strategic Pivot to ... BioHarvest Sciences Inc (BHST) secures landmark fragrance CDMO deal and narrows EBITDA loss guidance despite D2C headwinds. | ||
 BioHarvest Sciences Inc. Common Stock Q2 2026 Earnings Call Summary Moby summary of BioHarvest Sciences Inc. Common Stock's Q2 2026 earnings call | ||
 BioHarvest Sciences Q2 Earnings Call Highlights BioHarvest Sciences (NASDAQ:BHST) reported second-quarter 2026 revenue of $8.8 million, up 3.8% from $8.5 million a year earlier, while highlighting its first manufacturing and supply agreement within its contract development and manufacturing organization, or CDMO, business. Chairman and Chief Exe | ||
 BioHarvest posts higher Q2 revenue, secures manufacturing deal for premium fragrance compound BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) reported higher second-quarter revenue as the plant-based molecule developer shifted spending toward manufacturing capacity. Revenue for the quarter was $8.8 million, up 3.8% from a year earlier. Net loss narrowed to $3.7 million, or $0.17 per... | ||
 BioHarvest Sciences shares surge 11% after major fragrance manufacturing deal BioHarvest Sciences Inc. (NASDAQ:BHST) shares jumped 11. | ||
 BioHarvest Sciences Inc. (BHST) Reports Q2 Loss, Lags Revenue Estimates BioHarvest Sciences Inc. (BHST) delivered earnings and revenue surprises of -30.77% and -10.51%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Celldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue Estimates Celldex (CLDX) delivered earnings and revenue surprises of +9.62% and -98.75%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Phathom Pharmaceuticals, Inc. (PHAT) Reports Break-Even Earnings for Q2 Phathom Pharmaceuticals (PHAT) delivered earnings and revenue surprises of +100.00% and +1.71%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 BioHarvest lands $1.4M grant for AI-driven plant science BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) said on Wednesday it has received a 4.33 million NIS (about $1.4 million) grant from the Israel Innovation Authority to fund a new research initiative applying machine learning and computer vision to its plant cell culture programs. The update... | ||